MedTrace Logo

Evaluate the Glycemic Control of CKD-501 in Type 2 Diabetes Mellitus

NCT01030679 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 214

Last updated 2009-12-16

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and effectiveness of three doses of CKD-501 compared to placebo in lowering fasting plasma glucose levels in people with type 2 diabetes for 8 weeks.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

CKD-501 0.5mg

0.5 mg/tablet, orally, 1 tablet once daily for 8 weeks

DRUG

CKD-501 1mg

1 mg/tablet, orally, 1 tablet once daily for 8 weeks

DRUG

CKD-501 2mg

2 mg/tablet, orally, 1 tablet once daily for 8 weeks

DRUG

Placebo

orally, 1 tablet once daily for 8 weeks

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Dongseop Choi, MD.,Ph.D. · The Korea University Anam Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2008-10-31
Completion
2008-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01030679 on ClinicalTrials.gov